Seagen
Seagen, Inc. is a biotechnology company focused on the development and commercialization of targeted cancer therapies. Founded in 1993 and headquartered in Seattle, Washington, the company specializes in antibody-drug conjugates (ADCs), a novel class of medicines designed to deliver potent cytotoxic agents directly to cancer cells while sparing healthy tissue. Seagen’s mission is to transform the treatment landscape for patients with cancer by advancing innovative therapies that improve outcomes and quality of life.
The company’s flagship product, **Polivy (polatuzumab vedotin)**, is an ADC approved for the treatment of relapsed
In addition to ADCs, Seagen explores other therapeutic modalities, such as bispecific antibodies and immune checkpoint
Seagen is publicly traded on the NASDAQ under the ticker symbol **SGEN** and is committed to advancing